[go: up one dir, main page]

WO2003055979A3 - Anticorps se liant à blys selon un mode immunospécifique - Google Patents

Anticorps se liant à blys selon un mode immunospécifique

Info

Publication number
WO2003055979A3
WO2003055979A3 PCT/US2002/036496 US0236496W WO03055979A3 WO 2003055979 A3 WO2003055979 A3 WO 2003055979A3 US 0236496 W US0236496 W US 0236496W WO 03055979 A3 WO03055979 A3 WO 03055979A3
Authority
WO
WIPO (PCT)
Prior art keywords
blys
antibodies
immunospecifically bind
present
related molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/036496
Other languages
English (en)
Other versions
WO2003055979A2 (fr
Inventor
Steven M Ruben
Steven C Barash
Gil H Choi
Tristan J Vaughan
David Hilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to AU2002364954A priority Critical patent/AU2002364954A1/en
Priority to EP02802570A priority patent/EP1456347A4/fr
Priority to CA002467521A priority patent/CA2467521A1/fr
Publication of WO2003055979A2 publication Critical patent/WO2003055979A2/fr
Publication of WO2003055979A3 publication Critical patent/WO2003055979A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

la présente invention concerne des anticorps et molécules connexes qui se lient à BLyS selon un mode immunospécifique. Elle concerne également des méthodes et des compositions permettant de détecter ou de diagnostiquer une pathologie ou des troubles en rapport avec une expression aberrante de BLyS, ou avec une fonction inappropriée de BLyS, Ces compositions renferment des anticorps ou des fragments ou des variants de BLyS, ou bien des molécules connexes qui se lient à BLyS selon un mode immunospécifique. Cette invention concerne en outre des méthodes ou des compositions permettant de prévenir, de traiter ou d'atténuer une pathologie ou des troubles en rapport avec une expression aberrante de BLyS, ou avec une fonction inappropriée de BLyS, par administration à un animal d'une dose efficace d'un ou plusieurs anticorps ou fragments d'anticorps, ou bien de molécules connexes se liant à BLyS selon un mode immunospécifique.
PCT/US2002/036496 2001-11-16 2002-11-14 Anticorps se liant à blys selon un mode immunospécifique Ceased WO2003055979A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002364954A AU2002364954A1 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
EP02802570A EP1456347A4 (fr) 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique
CA002467521A CA2467521A1 (fr) 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US60/331,469 2001-11-16
US34081701P 2001-12-19 2001-12-19
US60/340,817 2001-12-19

Publications (2)

Publication Number Publication Date
WO2003055979A2 WO2003055979A2 (fr) 2003-07-10
WO2003055979A3 true WO2003055979A3 (fr) 2003-12-18

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036496 Ceased WO2003055979A2 (fr) 2001-11-16 2002-11-14 Anticorps se liant à blys selon un mode immunospécifique

Country Status (4)

Country Link
EP (1) EP1456347A4 (fr)
AU (1) AU2002364954A1 (fr)
CA (1) CA2467521A1 (fr)
WO (1) WO2003055979A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
US8198414B2 (en) 2006-11-30 2012-06-12 Medimmune Limited Anti-human IL-6 antibodies
US11203636B2 (en) 2017-02-01 2021-12-21 Yale University Treatment of existing left ventricular heart failure
US11384143B2 (en) 2018-01-05 2022-07-12 Novo Nordisk A/S Methods for treating IL-6 mediated inflammation without immunosuppression

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
DK1415659T3 (da) 1999-01-25 2011-10-03 Biogen Idec Inc BAFF, inhibitorer og anvendelse deraf i modulering af B-cellerespons
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
EA004635B1 (ru) 1999-08-17 2004-06-24 Байоджен, Инк. Рецептор baff (bcma), иммунорегуляторный агент
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609583T3 (es) 2000-06-16 2017-04-21 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1608730B1 (fr) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Recepteurs baff tronques
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
CA2534055A1 (fr) * 2003-08-01 2005-02-10 Genentech, Inc. Polypeptides de liaison avec sequences de diversite restreinte
US7833731B2 (en) * 2004-03-31 2010-11-16 Canon Kabushiki Kaisha Gold-binding protein and use thereof
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20080050381A1 (en) * 2004-08-31 2008-02-28 Tsutomu Takeuchi Antihuman Baff Antibody
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2626082C (fr) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Procedes et compositions destinees au traitement de patients atteints de maladies positives pour des auto-anticorps
EP1952150B1 (fr) 2005-11-23 2016-12-14 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
SI2139517T1 (sl) 2007-03-27 2013-09-30 Zymogenetics, Inc. Kombinacija inhibicije BLyS in mikofenolat mofetila za zdravljenje avtoimunske bolezni
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
US20210347873A1 (en) * 2016-07-06 2021-11-11 Shanghai Pharmaexplorer Co., Ltd. Blys antibody, preparation method therefor and application thereof
CA3178882A1 (fr) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. Proteines immunomodulatrices inhibitrices d'april et de baff et leurs procedes d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087977A2 (fr) * 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255558B1 (fr) * 2000-02-16 2006-06-14 Genentech, Inc. Anticorps anti-april et cellules hybridomes
ES2609583T3 (es) * 2000-06-16 2017-04-21 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087977A2 (fr) * 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1456347A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
US8198414B2 (en) 2006-11-30 2012-06-12 Medimmune Limited Anti-human IL-6 antibodies
US9005620B2 (en) 2006-11-30 2015-04-14 Medimmune Limited Compounds
US11203636B2 (en) 2017-02-01 2021-12-21 Yale University Treatment of existing left ventricular heart failure
US11384143B2 (en) 2018-01-05 2022-07-12 Novo Nordisk A/S Methods for treating IL-6 mediated inflammation without immunosuppression

Also Published As

Publication number Publication date
WO2003055979A2 (fr) 2003-07-10
AU2002364954A8 (en) 2003-07-15
EP1456347A2 (fr) 2004-09-15
EP1456347A4 (fr) 2006-08-02
CA2467521A1 (fr) 2003-07-10
AU2002364954A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
WO2003055979A3 (fr) Anticorps se liant à blys selon un mode immunospécifique
MXPA02012434A (es) Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
WO2002016411A3 (fr) Polypeptides de fixation et procedes associes
WO2003054216A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
DE60236646D1 (de) Anti-VEGF-2 Antikörper
WO2002097033A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs de trail
WO2002094192A3 (fr) Anticorps contre le facteur de necrose tumorale delta (april)
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
WO2002083849A3 (fr) Facteur de croissance endothélial vasculaire 2
DE602004029399D1 (fr)
WO2003057006A3 (fr) Utilisation d'anticorps diriges contre l'antigene muc18
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
WO2003085093A3 (fr) Anticorps se liant specifiquement a gmad
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
WO2004013287A3 (fr) Anticorps diriges contre le recepteur c3a
WO2005016236A3 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
WO2004003144A3 (fr) Anticorps qui se lient specifiquement a reg iv
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
WO2002079377A3 (fr) Anticorps a liaison immunospecifique avec les recepteurs 'trail'
WO2003086301A3 (fr) Anticorps se liant specifiquement a tr2
WO2002070563A3 (fr) Domaine de liaison de ligand au recepteur hormonal nucleaire
BR0306869A (pt) Composição farmacêutica orodispersìvel de piribedila
WO2002070558A3 (fr) Domaine de liaison du ligand du recepteur hormonal nucleaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2467521

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002802570

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002802570

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP